NO20020814D0 - Nye spiroforbindelser - Google Patents

Nye spiroforbindelser

Info

Publication number
NO20020814D0
NO20020814D0 NO20020814A NO20020814A NO20020814D0 NO 20020814 D0 NO20020814 D0 NO 20020814D0 NO 20020814 A NO20020814 A NO 20020814A NO 20020814 A NO20020814 A NO 20020814A NO 20020814 D0 NO20020814 D0 NO 20020814D0
Authority
NO
Norway
Prior art keywords
spiro compounds
new spiro
new
compounds
spiro
Prior art date
Application number
NO20020814A
Other languages
English (en)
Other versions
NO323514B1 (no
NO20020814L (no
Inventor
Takehiro Fukami
Akio Kanatani
Akane Ishihara
Yasuyuki Ishii
Toshiyuki Takahashi
Yuji Haga
Toshihiro Sakamoto
Takahiro Itoh
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of NO20020814D0 publication Critical patent/NO20020814D0/no
Publication of NO20020814L publication Critical patent/NO20020814L/no
Publication of NO323514B1 publication Critical patent/NO323514B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20020814A 1999-08-20 2002-02-19 Nye spiroforbindelser, fremgangsmate for fremstilling av slike, samt nevnte spiroforbindelser for medisinsk bruk. NO323514B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23357399 1999-08-20
JP2000137692 2000-05-10
PCT/JP2000/005427 WO2001014376A1 (en) 1999-08-20 2000-08-11 Novel spiro compounds

Publications (3)

Publication Number Publication Date
NO20020814D0 true NO20020814D0 (no) 2002-02-19
NO20020814L NO20020814L (no) 2002-04-15
NO323514B1 NO323514B1 (no) 2007-06-04

Family

ID=26531087

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020814A NO323514B1 (no) 1999-08-20 2002-02-19 Nye spiroforbindelser, fremgangsmate for fremstilling av slike, samt nevnte spiroforbindelser for medisinsk bruk.

Country Status (36)

Country Link
US (3) US6326375B1 (no)
EP (1) EP1204663B1 (no)
KR (1) KR100749713B1 (no)
CN (2) CN100457757C (no)
AR (1) AR029000A1 (no)
AT (1) ATE253064T1 (no)
AU (1) AU767229B2 (no)
BG (1) BG65805B1 (no)
BR (1) BR0013423A (no)
CA (1) CA2379103C (no)
CO (1) CO5200768A1 (no)
CZ (1) CZ2002533A3 (no)
DE (1) DE60006251T2 (no)
DK (1) DK1204663T3 (no)
DZ (1) DZ3175A1 (no)
EA (1) EA004507B1 (no)
EE (1) EE05248B1 (no)
ES (1) ES2206287T3 (no)
GE (1) GEP20053488B (no)
HK (1) HK1043123B (no)
HR (1) HRP20020102B1 (no)
HU (1) HUP0203107A3 (no)
IL (1) IL148119A0 (no)
IS (1) IS2420B (no)
MX (1) MXPA02001693A (no)
MY (1) MY130769A (no)
NO (1) NO323514B1 (no)
NZ (1) NZ517057A (no)
PE (1) PE20010645A1 (no)
PL (1) PL353743A1 (no)
PT (1) PT1204663E (no)
RS (1) RS50484B (no)
SK (1) SK286609B6 (no)
TR (1) TR200200408T2 (no)
TW (1) TWI279402B (no)
WO (1) WO2001014376A1 (no)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
US6462053B1 (en) * 1999-08-20 2002-10-08 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6803372B2 (en) * 1999-08-20 2004-10-12 Banyu Pharmaceutical Co., Ltd. Spiro compounds
CA2424622A1 (en) * 2000-10-03 2002-04-11 Clyde W. Hodge Use of neuropeptide-y antagonists in treatment of alcoholism
JP2004520299A (ja) * 2000-12-12 2004-07-08 ニューロジェン・コーポレーション スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類
EP1695977A3 (en) * 2000-12-12 2006-09-20 Neurogen Corporation Spiro [isobenzofuran-1,4'piperidin]-3-ones and 3H-spiroisobenzofuran-1, 4'-piperidines
ES2316486T3 (es) 2000-12-21 2009-04-16 Schering Corporation Antagonsitas de los receptores y5 del neuropeptido y heteroaril-urea.
US6946476B2 (en) 2000-12-21 2005-09-20 Schering Corporation Heteroaryl urea neuropeptide Y Y5 receptor antagonists
US6924291B2 (en) 2001-01-23 2005-08-02 Merck & Co., Inc. Process for making spiro isobenzofuranone compounds
WO2002094825A1 (fr) * 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
CA2454228C (en) 2001-07-24 2011-03-22 Merck & Co., Inc. Radiolabeled neuropeptide y y5 receptor antagonists
DE60231880D1 (de) * 2001-08-07 2009-05-20 Banyu Pharma Co Ltd Spiro isobenzofurane als neuropeptid y rezeptor antagonisten
CA2469790A1 (en) * 2001-12-17 2003-06-26 Merck & Co., Inc. Method for treating circadian rhythm disruptions
WO2003051397A1 (en) * 2001-12-17 2003-06-26 Merck & Co., Inc. Neuropeptide y5 receptor antagonists for treating depression, anxiety and dementia
US6605720B1 (en) 2002-01-28 2003-08-12 Merck & Co., Inc. Process for making spirolactone compounds
NZ534757A (en) * 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US7109207B2 (en) * 2002-06-27 2006-09-19 Schering Corporation Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
US7105526B2 (en) * 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004005262A2 (en) * 2002-07-02 2004-01-15 Schering Corporation New neuropeptide y y5 receptor antagonists
AU2003253925A1 (en) * 2002-07-18 2004-02-09 Banyu Pharmaceutical Co., Ltd. Combination therapy for the treatment of obesity
EP1558605A2 (en) * 2002-10-18 2005-08-03 Merck & Co., Inc. Process for making spirolactone compounds
EP1566384B1 (en) 2002-11-29 2009-06-17 Banyu Pharmaceutical Co., Ltd. Novel azole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
WO2004058264A1 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AR044283A1 (es) * 2003-05-19 2005-09-07 Merck & Co Inc Procedimeinto para preparar compuestos de espirolactona
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US20060160834A1 (en) * 2003-06-06 2006-07-20 Fong Tung M Combination therapy for the treatment of hypertension
US20070099884A1 (en) * 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US20050069244A1 (en) * 2003-09-25 2005-03-31 Miguel Dajer Flexible distributed wireless signal system and method
CA2540190A1 (en) * 2003-09-26 2005-04-07 Pfizer Products Inc. Use of npy y5 receptor antagonist for the treatment of circadian rhythm disorders
CA2540197A1 (en) * 2003-09-26 2005-04-07 Pfizer Products Inc. Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists
CN1938286A (zh) 2004-03-29 2007-03-28 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的二芳基三唑
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
AU2005247693A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[E]azulene derivatives and analogs thereof
ATE472531T1 (de) 2004-08-06 2010-07-15 Merck Sharp & Dohme Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
MX2007002033A (es) 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
TW200616968A (en) 2004-08-27 2006-06-01 Ono Pharmaceutical Co Compound having basic substituent and application thereof
WO2006028239A1 (ja) * 2004-09-07 2006-03-16 Banyu Pharmaceutical Co., Ltd. カルバモイル置換スピロ誘導体
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
RU2007124373A (ru) 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
AU2006208045B2 (en) * 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20060270650A1 (en) * 2005-05-26 2006-11-30 Macneil Tanya Combination therapy for the treatment of obesity
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
WO2007016028A2 (en) * 2005-07-28 2007-02-08 Merck & Co., Inc. Synthesis and crystalline forms of npy5 antagonist
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
JPWO2007024004A1 (ja) 2005-08-24 2009-03-05 萬有製薬株式会社 フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
US8193208B2 (en) 2005-09-09 2012-06-05 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
EP1953165B1 (en) 2005-11-10 2012-02-01 Msd K.K. Aza-substituted spiro derivative
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
JP2009521483A (ja) * 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
RU2008137593A (ru) * 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
AU2007221220A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
DK2007752T3 (da) 2006-03-31 2010-11-15 Janssen Pharmaceutica Nv Benzimidazol-2-yl-pyrimidiner og -pyraziner som modulatorer af histamin H4-receptoren
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
EP2040706A2 (en) * 2006-06-29 2009-04-01 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
EP2051712A2 (en) * 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
JP2010501561A (ja) * 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
CA2664358A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diarylketimine derivative
AU2007328995B2 (en) 2006-12-07 2012-04-26 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as VIa receptor antagonists
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
JP2010513384A (ja) 2006-12-22 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー スピロ−ピペリジン誘導体
CA2674518A1 (en) * 2006-12-22 2008-07-03 F.Hoffmann-La Roche Ag Spiro-piperidine derivatives
WO2008080844A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Azaspiro derivatives
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
EP2207549A1 (en) * 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
EA201070609A1 (ru) * 2007-11-14 2010-12-30 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
US7875618B2 (en) * 2007-11-30 2011-01-25 Wyeth Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
JP5593234B2 (ja) * 2008-03-11 2014-09-17 ユニバーシティー ヘルス ネットワーク ニューロペプチドｙ５ｒ（ｎｐｙ５ｒ）アンタゴニストを使用して癌を治療する方法
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
JP5635991B2 (ja) 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． イソニコチンアミドオレキシン受容体アンタゴニスト
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
US20110230493A1 (en) * 2008-11-21 2011-09-22 Pfizer Inc. 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
TW201111383A (en) 2009-05-29 2011-04-01 Wyeth Llc Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
JP2013510834A (ja) 2009-11-16 2013-03-28 メリテク ［１，５］‐ジアゾシン誘導体
CN103664873B (zh) 2009-12-30 2016-06-15 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
CN105025898B (zh) 2013-03-06 2018-01-23 詹森药业有限公司 组胺h4受体的苯并咪唑‑2‑基嘧啶调节剂
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US10076698B2 (en) 2016-05-17 2018-09-18 Sportsmedia Technology Corporation Automated or assisted umpiring of baseball game using computer vision
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CN113302189A (zh) 2018-11-20 2021-08-24 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
JP7443625B2 (ja) 2020-08-18 2024-03-05 メルク・シャープ・アンド・ドーム・エルエルシー ビシクロヘプタンピロリジンオレキシン受容体アゴニスト

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ258412A (en) * 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
AU756797B2 (en) * 1998-11-10 2003-01-23 Banyu Pharmaceutical Co., Ltd. Spiro-indolines as Y5 receptor antagonists

Also Published As

Publication number Publication date
AU767229B2 (en) 2003-11-06
US6326375B1 (en) 2001-12-04
NO323514B1 (no) 2007-06-04
CZ2002533A3 (cs) 2002-08-14
IS2420B (is) 2008-10-15
EA200200270A1 (ru) 2002-08-29
PT1204663E (pt) 2004-02-27
WO2001014376A1 (en) 2001-03-01
US6388077B1 (en) 2002-05-14
TWI279402B (en) 2007-04-21
CN100457757C (zh) 2009-02-04
HUP0203107A2 (hu) 2002-12-28
US20020052371A1 (en) 2002-05-02
SK2522002A3 (en) 2002-08-06
IS6267A (is) 2002-02-13
HK1043123B (zh) 2004-01-30
MY130769A (en) 2007-07-31
WO2001014376A8 (en) 2001-08-09
EP1204663B1 (en) 2003-10-29
CN1640877A (zh) 2005-07-20
CO5200768A1 (es) 2002-09-27
HK1043123A1 (en) 2002-09-06
ES2206287T3 (es) 2004-05-16
HRP20020102A2 (en) 2004-02-29
CN1202108C (zh) 2005-05-18
DK1204663T3 (da) 2004-02-09
HRP20020102B1 (en) 2005-04-30
EP1204663A1 (en) 2002-05-15
BG106390A (en) 2002-12-29
KR100749713B1 (ko) 2007-08-16
AU6476200A (en) 2001-03-19
EA004507B1 (ru) 2004-04-29
CN1370168A (zh) 2002-09-18
IL148119A0 (en) 2002-09-12
NZ517057A (en) 2003-08-29
DE60006251D1 (de) 2003-12-04
HUP0203107A3 (en) 2004-06-28
DE60006251T2 (de) 2004-05-13
BG65805B1 (bg) 2009-12-31
NO20020814L (no) 2002-04-15
YU10802A (sh) 2004-09-03
US6335345B1 (en) 2002-01-01
TR200200408T2 (tr) 2002-06-21
PE20010645A1 (es) 2001-06-07
EE200200082A (et) 2003-06-16
EE05248B1 (et) 2009-12-15
PL353743A1 (en) 2003-12-01
ATE253064T1 (de) 2003-11-15
GEP20053488B (en) 2005-04-25
DZ3175A1 (fr) 2001-03-01
BR0013423A (pt) 2002-05-07
KR20020021410A (ko) 2002-03-20
AR029000A1 (es) 2003-06-04
RS50484B (sr) 2010-03-02
MXPA02001693A (es) 2002-08-06
CA2379103A1 (en) 2001-03-01
CA2379103C (en) 2010-06-15
SK286609B6 (sk) 2009-02-05

Similar Documents

Publication Publication Date Title
NO20020814L (no) Nye spiroforbindelser
NO20000226L (no) Nye spiroazabicykliske heterocykliske forbindelser
NO20014518L (no) Nye forbindelser
DK1202994T3 (da) Nye forbindelser
NO20033715D0 (no) Nye sammensetninger
NO20021436L (no) Nye forbindelser
NO20020810L (no) Nye fenylpiperaziner
DK1237857T3 (da) Nye Phenalkyloxyphenylderivater
NO20015383L (no) Nye forbindelser
NO20015074L (no) Nye sammensetninger
PT1144411E (pt) Compostos espiro anti-histaminicos
NO20022847D0 (no) Nye substituerte tricykliske forbindelser
NO20030274L (no) Nye aryleten-sulfonamider
NO20015374D0 (no) Nye forbindelser
NO20013601D0 (no) Nye morfolinobenzamidsalter
NO20014629L (no) Nye forbindelser
NO20016273L (no) Nye forbindelser
NO995430D0 (no) Nye heterosykliske forbindelser
SE9904422D0 (sv) New compounds
SE9904418D0 (sv) New compounds
SE9900071D0 (sv) New compounds
SE9904228D0 (sv) New compounds
SE9900086D0 (sv) New compounds
SE9902762D0 (sv) New compounds
SE9904420D0 (sv) New compounds

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees